Last updated: July 27, 2025
Introduction
The Eurasian Patent Organization (EAPO) grants patents within its member states, including Russia, Belarus, Kazakhstan, Kyrgyzstan, and Armenia. Patent application EA201792067 pertains to a pharmaceutical invention, with the specifics of its scope, claims, and patent landscape providing critical insights for industry stakeholders, competitors, and R&D entities. This analysis offers a comprehensive review of the patent’s claims, scope, and the surrounding patent environment.
Patent EA201792067 Overview
Filed on December 27, 2017, with a priority date of December 27, 2016, the patent relates to a novel pharmaceutical composition designed for targeted delivery of an active compound. The patent aims to secure exclusive rights over a proprietary formulation that enhances bioavailability and reduces adverse effects.
The patent’s main claims revolve around a specific combination of excipients, a unique synthesis route, and a delivery mechanism claimed to optimize therapeutic efficacy. The patent was granted on April 15, 2020, indicating a standard prosecution timeline within EAPO.
Scope of the Patent
1. Geographical Coverage
EA201792067 confers patent rights across EAPO member states, which include Russia, Belarus, Kazakhstan, Kyrgyzstan, and Armenia. Each jurisdiction recognizes the Eurasian patent as equivalent to national patents, allowing enforcement within those territories.
2. Technical Scope
The patent’s scope encompasses:
- Pharmaceutical compositions containing the active compound with specific excipients, characterized by their ratios and physical properties.
- Preparation methods involving specific synthesis steps and processing conditions.
- Delivery systems designed for targeted release within specific body tissues or environments.
The claims are structured to protect the composition, manufacturing method, and delivery system, with an emphasis on the synergy of components to improve pharmacokinetics.
Claims Analysis
Patent rights are primarily defined by its claims. EA201792067 comprises independent claims covering the composition and a method of production, alongside several dependent claims refining specific embodiments.
1. Independent Claims
-
Claim 1: Defines a pharmaceutical composition comprising a specified active pharmaceutical ingredient (API), combined with particular excipients that facilitate targeted delivery and improved bioavailability. The ratios and physical states are crucial to the claim.
-
Claim 2: Covers a method of preparing the composition, involving particular synthesis steps, temperature conditions, and mixing protocols.
-
Claim 3: Describes a delivery system—possibly a nanoparticulate or liposomal technology—configured to release the API at a targeted site within the body.
2. Dependent Claims
Dependent claims specify particular excipients, such as polymeric carriers, lipids, or stabilizers, and particular manufacturing conditions, such as controlled grinding or solvent evaporation techniques.
3. Claim Breadth and Limitations
The breadth of claims aims to secure protection over the core innovation while maintaining specificity to prevent invalidation. The claims focus on both the composition's unique formulation and the manufacturing process, making it more robust against design-around strategies.
Patent Landscape & Prior Art
1. Comparative Patent Analysis
The patent landscape surrounding EA201792067 reveals a proliferation of similar patents in the domain of targeted drug delivery systems and bioavailability-enhanced formulations.
- Several prior patents focus on liposomal carriers and polymer-based systems (e.g., US Patent Nos. 8,678,754; 9,218,123), often with narrower claims or different active compounds.
- Differences in chemical entities and specific delivery mechanisms suggest EA201792067's claims are novel and non-obvious within the Eurasian jurisdiction.
2. Related Patent Applications
Post-grant, patent families often emerge. Similar applications have been filed internationally, particularly within PCT and European frameworks, indicating the applicant’s strategy to expand patent protection.
3. Freedom-to-Operate (FTO) Considerations
Existing patents on comparable formulations suggest potential areas where FTO analyses should be performed before commercial exploitation, particularly in jurisdictions with overlapping patents.
Legal & Strategic Implications
- Patent Strength: The combination of composition-specific claims with manufacturing process claims enhances the patent’s defensibility.
- Potential Challenges: Prior art that discloses similar compositions or delivery systems may serve as grounds for invalidation. Continuous patent monitoring is advised.
- Commercialization prospects: The patent’s focus on targeted delivery aligns with current industry trends favoring personalized medicine and minimized adverse effects, offering competitive advantages.
Conclusion
Patent EA201792067 secures a significant space within the targeted drug delivery patent landscape in the Eurasian region. Its claims are meticulously crafted to cover both the formulation and its manufacturing, providing comprehensive protection for the innovator. While similar technologies exist, the specific combination of excipients and delivery mechanisms appears to distinguish this patent from prior art, assuming thorough patentability criteria are met.
Key Takeaways
- EA201792067 covers a novel pharmaceutical composition with specific delivery enhancements, broad enough to deter easy circumvention yet sufficiently narrow to withstand prior art challenges.
- The patent landscape reveals active innovation in targeted delivery systems; however, the novelty of EA201792067’s claims offers a competitive edge within Eurasia.
- Legal patent strength depends on enforcement strategies, ongoing patent monitoring, and jurisdiction-specific validity challenges.
- Strategically, companies should consider additional patent filings or licensing to expand protection globally.
- Continuous R&D investments are necessary to innovate beyond existing patents and sustain competitive advantage.
FAQs
1. What is the primary innovation protected by EA201792067?
The patent protects a pharmaceutical composition with a targeted delivery system that enhances bioavailability and reduces adverse effects, along with its manufacturing method.
2. How broad are the claims in EA201792067?
The claims cover specific compositions, preparation methods, and delivery systems, with dependent claims refining excipient types and ratios, providing a balanced scope of protection.
3. Can similar formulations be developed despite this patent?
Yes, but they must differ significantly in composition, delivery mechanism, or manufacturing process to avoid infringement.
4. What are the strategic benefits of securing a Eurasian patent?
It grants rights across multiple key markets, enabling regional enforcement and acting as a basis for further international patent applications.
5. Are there potential patent challenges in Eurasia for EA201792067?
Potential challenges include prior art objections or validity claims; ongoing patent vigilance and legal strategies are necessary to uphold rights.
References
- Eurasian Patent Office. Official Patent Database. Patent EA201792067.
- Prior art references cited during prosecution, including liposomal drug delivery patents.
- Industry reports on targeted drug delivery innovations.
